Navigation Links
United Therapeutics Corporation Reports Second Quarter 2013 Financial Results
Date:7/25/2013

s is presented below (in thousands, except per share data):Three Months Ended June 30,20132012Net income, as reported

$

79,864$

72,316Adjust for non-cash charges:Interest expense

4,5203,879Income tax expense

38,65530,974License fees

——Depreciation and amortization

7,6806,292Impairment charges

—4,839

(1)Share-based compensation expense (benefit)

32,9869,447Earnings before non-cash charges

$

163,705$

127,747Earnings before non-cash charges per share:Basic

$

3.29$

2.42Diluted

$

3.11$

2.37Weighted average number of common shares outstanding:Basic

49,80052,747Diluted

52,64853,942(1)

Consists of a $6.8 million impairment loss relating to a contract-based intangible asset, upon the termination of the underlying license agreement during the three months ending June 30, 2012, net of the $2.0 million of deferred revenue we recognized as a result of the terminated license agreement and the termination of our obligation to perform future services. Conference CallWe will host a half-hour teleconference on Thursday, July 25, 2013, at 9:00 a.m. Eastern Time. The teleconference is accessible by dialing 1-877-351-5881, with international callers dialing 1-970-315-0533. A rebroadcast of the teleconference will be available for one week by dialing 1-855-859-2056, with international callers dialing 1-404-537-3406 and using access code 9978344.

This teleconference is also being webcast and can be accessed via our website at http://ir.unither.com/events.cfm.

About United TherapeuticsUnited Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions.

<
'/>"/>
SOURCE United Therapeutics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. United Therapeutics Corporation to Announce Second Quarter 2013 Financial Results Before Market Open on Thursday, July 25, 2013
2. Before the Bell Scans: Pharmacyclics, United Therapeutics, Impax Laboratories, and Star Scientific
3. Mapi Pharma Granted United States Patent for Pain Relief Medication "Tapentadol"
4. Centre for Sight First in the United Kingdom to Utilize TrueVision® 3D Visualization During Femtosecond Laser Cataract Surgery
5. Prevagen® is the Number One Branded Memory Supplement in the United States
6. SPIE on Global Team Proposing ‘international Year of Light’ at United Nations
7. United Airlines and AltAir Fuels to Bring Commercial-Scale, Cost-Competitive Biofuels to Aviation Industry
8. Despite Lucentiss Recent Expanded Label for Diabetic Macular Edema, Avastin Remains the Preferred Intravitreal Therapy for Diabetic Macular Edema in the United States
9. Atlantic Peptides Teams Up with a United Kingdom Company to Offer cGMP Peptides and API
10. SoundConnect Announces Lync Release in the United States
11. United Therapeutics Corporation To Announce First Quarter 2013 Financial Results Before Market Open On Thursday, April 25, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... ... September 04, 2015 , ... November Research ... services and software tools to pharmaceutical and life sciences organizations, today announced the ... Mobile is a mobile data intake solution that enables field sales representatives, clinical ...
(Date:9/3/2015)...  Vermillion, Inc. (NASDAQ: VRML ), a bio-analytical ... Herbert Fritsche , Ph.D., the Lab Director of ... of the 2015 Abbott Award, given by the International ... to the field of basic or clinical oncology. Dr. ... in Zakopane, Poland . Prior ...
(Date:9/3/2015)... ... 03, 2015 , ... Park Systems announced that they will host ... 9am PST. The webinar will focus on the methods and materials for additive manufacturing ... manufacturing is a broad term that encompasses “addition or fusion” of materials to create ...
(Date:9/2/2015)... DUBLIN , Sept. 2, 2015 /PRNewswire/ ... has announced the addition of Jain PharmaBiotech,s ... Companies" to their offering. ... the pharmaceutical and biotechnology industries is anticipated. ... of drug development - from formulations for ...
Breaking Biology Technology:November Research Group’s PRIMO Mobile Goes Live at Allergan Japan 2Vermillion Announces Dr. Herbert Fritsche as Recipient of the 2015 Abbott Award from the International Society of Oncology and Biomarkers 2Park Systems Announces Webinar on 3D Printing and Additive Manufacturing for Nano-Scientists, Researchers in Nanotechnology and Engineers 2Park Systems Announces Webinar on 3D Printing and Additive Manufacturing for Nano-Scientists, Researchers in Nanotechnology and Engineers 3Park Systems Announces Webinar on 3D Printing and Additive Manufacturing for Nano-Scientists, Researchers in Nanotechnology and Engineers 4Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 2Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 3
... market, EDMONTON, Aug. 27 /PRNewswire/ - Small ... bring nanotechnology products to,world markets can now access ... centre in Edmonton,s Research Park., The Alberta ... supported by $11.5 million in total funding with,contributions ...
... to put auto-injectable ... supplies list, SILVER SPRING, Md., Aug. 27 A ... found that 72% of school,nurses have students with a known ... not provided the school with auto-injectable,epinephrine. Also known as adrenaline, ...
... relapse, with use of Gleevec after surgery are basis for FDA, EMEA, Swissmedic ... filings, - Historically, one ... ... therapeutic approaches to patients with rare diseases, EAST ...
Cached Biology Technology:New nanotechnology centre helps turn big ideas into real products 2New nanotechnology centre helps turn big ideas into real products 3Video: New Survey Shows Three in Four School Nurses Have Students at Risk for Severe Allergic Reactions Who Do Not Bring Auto-Injectable Epinephrine to School 2Video: New Survey Shows Three in Four School Nurses Have Students at Risk for Severe Allergic Reactions Who Do Not Bring Auto-Injectable Epinephrine to School 3Video: New Survey Shows Three in Four School Nurses Have Students at Risk for Severe Allergic Reactions Who Do Not Bring Auto-Injectable Epinephrine to School 4Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery 2Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery 3Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery 4Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery 5Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery 6Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery 7Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery 8Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery 9Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery 10Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery 11Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery 12
(Date:8/6/2015)... CITY, Calif. , Aug. 6, 2015 /PRNewswire/ ... Valley) will visit Crossmatch ™ to learn ... networks and protect data. Crossmatch is a world ... whose technologies and expertise are helping federal agencies ... efficiency and security.   "The vast ...
(Date:8/5/2015)... Calif. , Aug. 5, 2015 The ... continuous growth in applications, penetration into newer sectors, and ... year. The global biosensors space has seen the entry ... the market so far. (Photo - ... & Sullivan, Analysis of the Global Biosensors Market ...
(Date:7/31/2015)... China , 31 de julio de 2015 /PRNewswire/ ... Genómica (ICG-10,  www.icg-10.org ) del 22 al 25 de ... . La conferencia celebra su décimo aniversario ... ha convertido en una de las reuniones anuales más ... y es una de las conferencias científicas más dinámicas, ...
Breaking Biology News(10 mins):Rep. Honda to Visit Crossmatch in Redwood City 2Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
... technique for reprogramming human adult cells could greatly improve the ... in a range of therapeutic applications to repair or replace ... is published in the peer-reviewed journal Cellular Reprogramming , ... free online. Stem cells offer great promise ...
... available in French . , Eradicating smallpox was ... but new research shows initiatives of this kind are not ... think. McGill University Biologist Dr. Jonathan Davies explains that reducing ... is a far more effective and efficient strategy than trying ...
... found in both coconut oil and human breast milk ... thanks to a bioengineering graduate student from the UC San ... delivery system" published in the journal ACS Nano ... directly to skin-dwelling bacteria ( Propionibacterium acnes ) that cause ...
Cached Biology News:Novel strategy for generating induced pluripotent stem cells for clinical use is safe and efficient 2Trying to eradicate a disease is a waste of money: researcher 2Treat acne with coconut oil and nano-bombs 2
SCP-1 (P-17)...
Immunogen: Purified native p24 from strain IIIB. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biotin d anti-mouse Tim-1...
Mouse monoclonal [MLM544] to cardiac Myosin light chain 1 ( Abpromise for all tested applications). entrezGeneID: 4634 SwissProtID: P08590...
Biology Products: